Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $205.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by Evercore ISI from $191.00 to $205.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other analysts also recently weighed in on ASND. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a buy rating and a $200.00 price target for the company. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a report on Wednesday, September 4th. Jefferies Financial Group upped their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a research note on Tuesday, August 13th. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a buy rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company cut their price objective on Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research note on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of Moderate Buy and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $153.43 on Tuesday. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The stock has a 50-day moving average price of $132.94 and a 200 day moving average price of $136.52. The company has a market capitalization of $8.93 billion, a P/E ratio of -15.49 and a beta of 0.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Private Ocean LLC bought a new stake in Ascendis Pharma A/S in the first quarter valued at $36,000. GAMMA Investing LLC increased its holdings in shares of Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares during the period. Quadrant Capital Group LLC lifted its position in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Finally, Bessemer Group Inc. grew its position in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.